TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at least 18 years or greater~* Symptomatic low ejection fraction heart failure (weak heart muscle)~* Receiving any dose of a beta blocker for the treatment of HF (unless not able to tolerate)~* Kidney function not more than mild or moderately impaired~* High blood potassium (\>5.0 mEq/L) currently while receiving medications for heart failure OR normal blood potassium currently but previously had high potassium in the12 months prior to screening which caused a permanent reduction or discontinuation of heart failure medications~* Hospitalization for heart failure or treatment in an out patient setting with intravenous medications within the last 12 months before screening.~Exclusion Criteria:~* Current acute decompensated HF, within 4 weeks before screening. Subjects with a discharge from a hospitalization for acute decompensation of HF longer than 4 weeks before screening may be included~* Significant primary aortic or mitral valvular heart disease (except secondary mitral regurgitation due to left ventricular dilatation)~* Heart transplantation or planned heart transplantation (i.e., currently on a heart transplant waiting list) during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Patiromer (Type: EXPERIMENTAL): Subjects will be randomized to receive a daily dose of patiromer with possible dose adjustments based on subsequent local serum potassium levels.
- Group 2: Placebo (Type: PLACEBO_COMPARATOR): Subjects will be randomized to receive a daily dose of placebo with possible dose adjustments based on subsequent local serum potassium levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optoacoustic Images Versus Imagio® Ultrasound

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* One analyzable mass per patient: BI-RADS 3 and 4a, 4b, 4c and 5 masses as declared by clinical site investigator via PIONEER study inclusion criteria and categorized as BIRADS 3, 4a, 4b 4c and 5 by conventional diagnostic ultrasound (CDU)~* Masses declared to be in the PIONEER Intention to Diagnose (ITD)/analysis population, including high risk cases per original PIONEER protocol~* Patient age, indication for study entry and available medical history~* Evaluable mammograms and OA and IUS video loops and stills for each mass~Exclusion Criteria:~* Critical missing IUS or OA still image and/or video loop views or incorrect IUS or OA stills and video loops that would preclude a case from being evaluated by readers~* Reader-02 Proficiency Test and training cases

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imagio IUS (Type: ACTIVE_COMPARATOR): Read 1 (Control): History + Mammogram (if available) + IUS (Imagio Ultrasound) stills and videos provided), IUS Probability of Malignancy (POM) and Breast Imaging Reporting and Data System (BI-RADS) scored and the data form then locked.
- Imagio (IUS+OA) (Type: EXPERIMENTAL): Read 2 (Test): History + Mammogram (if available) + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). Imagio (IUS+OA) POM and Breast Imaging Reporting and Data System (BI-RADS) assigned after viewing the SenoGram® output. The dataform is locked.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Meets all of the following conditions:~  * A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)~ * Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF) with ≥ 8% steatosis~ * Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5 kPa~    * OR~ * A historical liver biopsy consistent with NASH and non-cirrhotic fibrosis~* Platelet count ≥ 100,000/mm\^3~* Creatinine Clearance (CLcr ) as calculated by the Cockcroft-Gault equation ≥ 60 ml/min~Key Exclusion Criteria:~* Pregnant or lactating females~* Alanine aminotransferase (ALT) \> 5 x upper limit of the normal range (ULN)~* Other causes of liver disease including autoimmune, viral, and alcoholic liver disease~* Cirrhosis of the liver~  * Prior history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding~* Body mass index (BMI) \< 18 kg/m\^2~* International normalized ratio (INR) \> 1.2 unless on anticoagulant therapy~* Total bilirubin \> 1 x ULN, except with diagnosis of Gilbert's syndrome~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Firsocostat 5 mg (Type: EXPERIMENTAL): Participants will receive firsocostat 1 x 5 mg + 1 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
- Firsocostat 20 mg (Type: EXPERIMENTAL): Participants will receive firsocostat 2 X 10 mg + 2 x placebo matched to firsocostat 5 mg for 12 weeks.
- Placebo (Type: EXPERIMENTAL): Participants will receive 2 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-ingredient Supplement for Strength and Power

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be familiar with the three main powerlifting movements (squat, bench and deadlift)~* Must have one month training with a designated strength coach to understand the expectations of the strength coach and movement patterns for performance~* Have no pre-existing musculoskeletal disorders~* Participate in the three-week supplement wash out prior to beginning the experiment (except for basic protein supplements and multivitamins)~Exclusion Criteria:~* Female

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- T+ Supplement (Type: ACTIVE_COMPARATOR): This arm requires the participants to take a prescribed dose of the T+ supplement for 4 weeks while completing an exercise regiment.
- Placebo (Type: PLACEBO_COMPARATOR): This arm requires the participants to take a prescribed dose of a calorie matched placebo for 4 weeks while completing an exercise regiment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* This study will only include participants who were enrolled in the FIGARO-DKD study (NCT02545049) and had received up to 20 mg finerenone or placebo for ≥24 months.~* For each participant, pharmacokinetic (PK) plasma samples from Visit 3 and at least 2 other Visits (Visit 5, Visit 8, Visit 11) must be available on storage from the main study FIGARO-DKD.~Exclusion Criteria:~* Participants which did not show overall compliance of 80 to 120% with study intervention in FIGARO-DKD.~* Participants which were not part of the full analysis set (FAS) of FIGARO-DKD.~* Participants with known fatal outcome.~* Participants with baseline estimated glomerular filtration rate (eGFR) ≤25 mL/min/1.73m\^2.~* Participants with low baseline risk (normal albuminuria and eGFR≥60 mL/min/1.73m\^2).~* Sponsor request (after discussion with the investigator), for reasons such as a significant protocol deviation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Finerenone (Type: EXPERIMENTAL): Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nebivolol in the Supine Hypertension of Autonomic Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female and aged 18 years or over.~* Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic Failure (Parkinson Disease, Multiple System Atrophy and Pure Autonomic Failure).~* A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing.~* Supine hypertension, defined as a systolic blood pressure \>150 mm Hg or diastolic blood pressure \> 90 mm Hg.~* Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.~Exclusion Criteria:~* Have changed dose, frequency and or type of prescribed medication, within two weeks of study start.~* Women of childbearing potential who are not using a medically accepted contraception.~* Have, in the investigator's opinion, any significant cardiac, systemic, hepatic, or renal illness.~* Diabetes mellitus or insipidus.~* In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing.~* In the investigator's opinion, are unable to adequately co-operate because of individual or family situation.~* In the investigator's opinion, are suffering from a mental disorder that interferes with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major depression, dementia.~* Are not able or willing to comply with the study requirements for the duration of the study.~* Persons on drugs with beta-blocking potential (e.g., amiodarone), persons taking scheduled or as needed nitrates and persons on drugs with alpha-blocking potential (e.g. tamsulosin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo capsule (Type: PLACEBO_COMPARATOR): Placebo capsule
- Nebivolol 5 mg (Type: EXPERIMENTAL): Nebivolol 5 mg capsule
- Metoprolol tartrate 50 mg (Type: ACTIVE_COMPARATOR): Metoprolol tartrate 50 mg single oral dose
- Sildenafil 25 mg (Type: ACTIVE_COMPARATOR): Sildenafil 25 mg single oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients aged 18 years or older~* Meet criteria for diagnosis of diabetic neuropathy~* Average daily pain scores greater than or equal to 4 by Visual Analog Scale~* Ability to give informed consent~* No pregnancy~Exclusion Criteria:~* Patients with clinically significant psychiatric disorders requiring vigorous interventions, i.e., moderate to severe depressive disorder, psychotic disorders, PTSD, obsessive compulsive disorder, panic disorder, substance abuse, or personality disorders, or active suicidal/homicidal ideations, or past history of active suicidal ideation and/or attempts~* Patients on gabapentin which cannot be discontinued, meaning a dose greater than 1200mg. If a patient is on a dose of gabapentin that is less than 1200mg and he or she is willing to stop taking the medication, he or she can participate in the study. These patients must take the last dose of gabapentin the night before starting the study.~* Patients being non-compliant with diabetic control~* Inability to wear the LifeShirt~* Unable to participate or answer questions using a personal digital assistant input device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: EXPERIMENTAL): Pregabalin medication
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of the Effects of Montelukast in Patients With Chronic Cough

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic cough: cough persisting for more than 8 consecutive weeks~Exclusion Criteria:~* Current use of ACE-inhibitors~* Use of systemic steroids in the last 4 weeks~* COPD~* Pregnancy~* Concomitant severe disease~* Smoking

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: ACTIVE_COMPARATOR): Montelukast tablets: adults - 10 mg, children - 5mg taken daily for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chicken-Diet vs. Enalapril to Reduce Albuminuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes mellitus (according to World Health Organization criteria) attending the Endocrine Division's outpatient clinic at Hospital de Clínicas de Porto Alegre, Brazil. Patients were selected according to the following criteria: age \<75 years, A1c \<10%, 24-hour UAER 20 mcg/min and 199 mcg/min confirmed at least twice in a 6-month period, serum triglycerides \<400 mg/dl and normal liver and thyroid function tests.~Exclusion Criteria:~* Patients were excluded from the study if they had BMI \>34 kg/m2, serum creatinine \>1.5 mg/dl, repeated episodes of urinary tract infection, other renal diseases, symptomatic autonomic neuropathy, heart failure, and acute myocardial infarction, coronary artery revascularization procedures or stroke within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Single or multiple draining fistulas~* Crohn's disease of at least 3 months' duration,~Exclusion Criteria:~* Crohn's disease complications for which surgery might be indicated~* Positive stool culture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. High-output shock~2. Cardiovascular SOFA score of \> 4~3. Cardiac Index \> 2.4 liters/min/BSA 1.73m2~4. Indwelling arterial line already present as part of standard care~5. Age \> 21 years of age~6. Signed consent form~7. Use of indwelling urinary catheter as standard care expected at least for 12 hours during the study interventions~Exclusion Criteria:~1. Patients with acute coronary syndrome~2. Patients with a known history of vasospasm~3. Patients with a history of asthma~4. Patients currently experiencing bronchospasm~5. Patients with active bleeding with an anticipated need for \> 4 units of PRBC or Hemoglobin \< 7g/dL or any other condition that would contraindicate drawing serial blood samples

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Angiotensin (Type: ACTIVE_COMPARATOR): The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for mean arterial pressure (MAP) goals as outlined in the protocol.
- Control (Type: PLACEBO_COMPARATOR): Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with plaque psoriasis for at least 6 months.~* Have plaque psoriasis covering at least 15% of their total body.~* Be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment).~* Be willing and able to comply with scheduled visits, treatment plan and other study procedures.~Exclusion Criteria:~* Currently have non-plaque forms of psoriasis or drug-induced psoriasis.~* Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy.~* Subject is participating in another trial using an investigational agent or procedure.~* Women who are pregnant or breast-feeding or considering becoming pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be of Chinese ancestry~* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to study start~* Have plaque-type psoriasis covering at least 10% of total BSA at screening and at the time of study start~* Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater at study start~* Must be candidates for phototherapy or systemic treatment of psoriasis (either naive or history of previous treatment)~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis~* Have current drug-induced psoriasis~* Have used any investigational drug within the previous 4 weeks~* Have used any biologic within the previous 3 months~* Be known to be infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16
- 002 (Type: EXPERIMENTAL): placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete